Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:LIPONASDAQ:MTVANASDAQ:NEUPNASDAQ:ONCR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLIPOLipella Pharmaceuticals$1.65-30.1%$2.62$1.61▼$12.00$10.54M0.44725,115 shs189,783 shsMTVAMetaVia$0.68-3.4%$0.76$0.63▼$5.30$13.71M0.18167,951 shs51,705 shsNEUPNeuphoria Therapeutics$6.80+2.7%$5.84$2.12▼$12.55$12.44M0.4625,757 shs5,769 shsONCROncorus$0.13$0.07$0.01▼$0.47$3.29M3.61.33 million shs135,947 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLIPOLipella Pharmaceuticals-30.08%-35.52%-43.69%-36.29%-67.62%MTVAMetaVia-3.41%-7.65%-22.78%-56.38%+67,609,900.00%NEUPNeuphoria Therapeutics+2.72%-0.29%+22.97%+26.39%+679,999,900.00%ONCROncorus0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationLIPOLipella Pharmaceuticals1.4729 of 5 stars0.05.00.00.01.93.30.0MTVAMetaVia1.5658 of 5 stars3.50.00.00.00.60.01.3NEUPNeuphoria TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AONCROncorusN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceLIPOLipella Pharmaceuticals 0.00N/AN/AN/AMTVAMetaVia 3.00Buy$7.501,009.30% UpsideNEUPNeuphoria Therapeutics 3.00Buy$21.00208.82% UpsideONCROncorus 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ONCR, MTVA, LIPO, and NEUP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2025MTVAMetaViaMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.00 ➝ $3.004/16/2025MTVAMetaViaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.003/21/2025MTVAMetaViaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.00(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookLIPOLipella Pharmaceuticals$540K13.66N/AN/A$1.59 per share1.04MTVAMetaViaN/AN/AN/AN/A$0.92 per shareN/ANEUPNeuphoria Therapeutics$10K1,278.40N/AN/A$15.85 per share0.43ONCROncorusN/AN/AN/AN/A$2.33 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateLIPOLipella Pharmaceuticals-$5.02M-$4.08N/A∞N/A-988.83%-224.08%-172.88%N/AMTVAMetaVia-$27.59MN/A0.00N/AN/AN/A-222.13%-123.85%8/13/2025 (Estimated)NEUPNeuphoria Therapeutics-$15.49MN/A0.00N/AN/AN/AN/AN/AN/AONCROncorus-$77.42M-$3.49N/A∞N/AN/AN/AN/AN/ALatest ONCR, MTVA, LIPO, and NEUP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2025Q3 2025NEUPNeuphoria Therapeutics-$0.47$6.55+$7.02$6.55N/A$15.00 million5/14/2025Q1 2025LIPOLipella PharmaceuticalsN/A-$0.64N/A-$0.64N/A$0.13 million5/14/2025Q1 2025MTVAMetaVia-$0.57-$0.36+$0.21-$0.36N/AN/A3/27/2025Q4 2024LIPOLipella Pharmaceuticals-$2.43-$1.19+$1.24-$1.19N/A$0.17 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthLIPOLipella PharmaceuticalsN/AN/AN/AN/AN/AMTVAMetaViaN/AN/AN/AN/AN/ANEUPNeuphoria TherapeuticsN/AN/AN/AN/AN/AONCROncorusN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioLIPOLipella PharmaceuticalsN/A6.216.21MTVAMetaViaN/A1.551.55NEUPNeuphoria TherapeuticsN/A11.0111.01ONCROncorusN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipLIPOLipella Pharmaceuticals74.31%MTVAMetaVia1.37%NEUPNeuphoria Therapeutics15.90%ONCROncorus20.07%Insider OwnershipCompanyInsider OwnershipLIPOLipella Pharmaceuticals32.11%MTVAMetaVia0.80%NEUPNeuphoria Therapeutics0.69%ONCROncorus17.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableLIPOLipella Pharmaceuticals44.47 million3.03 millionNot OptionableMTVAMetaVia819.59 million19.43 millionN/ANEUPNeuphoria TherapeuticsN/A1.88 million1.87 millionN/AONCROncorus6426.09 million21.63 millionOptionableONCR, MTVA, LIPO, and NEUP HeadlinesRecent News About These CompaniesRFL Rafael Holdings, Inc.August 1, 2024 | seekingalpha.comOncorus Inc rdinary Shares Stock (OTC:ONCR) Dividends: History, Yield and DatesFebruary 26, 2024 | benzinga.comOncorus, Inc. (ONCR) stock price, news, quote & history – Yahoo FinanceDecember 29, 2023 | uk.finance.yahoo.comComera Life Sciences Holdings IncDecember 18, 2023 | investing.comOncorus Inc Ordinary SharesOctober 28, 2023 | morningstar.comONCR Historical DataOctober 16, 2023 | investing.comOncorus Inc. (ONCR) receives a Buy rating from Maxim GroupJune 21, 2023 | knoxdaily.comTaking a look at what insiders are doing to gauge the Oncorus Inc. (ONCR)’s directionJune 16, 2023 | knoxdaily.comWhat's Going On With Oncorus (ONCR) Stock Friday?June 16, 2023 | msn.comMaxim Group gives a Buy recommendation for Oncorus Inc. (ONCR)June 15, 2023 | knoxdaily.comONCR price target predicted to rise nearly $1.50 in 12 monthsJune 9, 2023 | knoxdaily.comOncorus could file for bankruptcy as most employees laid off; down 43%June 2, 2023 | msn.comDays-to-cover ratio for ONCR declines to 2.51 due to decline in short interestJune 1, 2023 | knoxdaily.comOncorus Announces Workforce Reduction PlanJune 1, 2023 | finance.yahoo.comOncorus, Inc.: Oncorus Reports First Quarter 2023 Financial Results and Provides Business UpdatesMay 23, 2023 | finanznachrichten.deRecap: Oncorus Q1 EarningsMay 22, 2023 | msn.comOncorus Reports First Quarter 2023 Financial Results and Provides Business UpdatesMay 22, 2023 | finance.yahoo.comOncorus, Inc.: Oncorus Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdatesMarch 24, 2023 | finanznachrichten.deOncorus Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdatesMarch 24, 2023 | finance.yahoo.comFor some biotechs moving on from SVB, not all traditional banks are an optionMarch 15, 2023 | bizjournals.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeONCR, MTVA, LIPO, and NEUP Company DescriptionsLipella Pharmaceuticals NASDAQ:LIPO$1.65 -0.71 (-30.08%) As of 06/20/2025 03:59 PM EasternLipella Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD). Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.MetaVia NASDAQ:MTVA$0.68 -0.02 (-3.41%) As of 06/20/2025 04:00 PM EasternMetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc., formerly known as NeuroBo Pharmaceuticals Inc., is based in CAMBRIDGE, Mass.Neuphoria Therapeutics NASDAQ:NEUP$6.80 +0.18 (+2.72%) As of 06/20/2025 03:58 PM EasternNeuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.Oncorus NASDAQ:ONCROncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company develops ONCR-021 for the treatment of non-small cell lung cancer, renal cell carcinoma, melanoma, and anaplastic thyroid cancer; and ONCR-788 for the treatment of small cell lung cancer, neuroendocrine prostate, and other neuroendocrine cancers. Oncorus, Inc. was incorporated in 2015 and is headquartered in Andover, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
